United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - risk summary there are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream (augmented) to women who are breastfeeding. it is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for betamethasone dipropionate cream (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream (augmented) or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breastfeeding women not to apply betamethasone dipropionate cream (augmented) directly to the nipple and areola to avoid direct infant exposure [see use in specific populations ( error! hyperlink reference not valid. )] .

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - risk summary there are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream (augmented) to women who are breastfeeding. it is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for betamethasone dipropionate cream (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream (augmented) or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breast

Israel - English - Ministry of Health

bayer israel ltd - interferon beta 1b - powder and solvent for solution for injection - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.

United States - English - NLM (National Library of Medicine)

warrick pharmaceuticals corporation - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - ointment - 0.5 mg in 1 g - augmented betamethasone dipropionate ointment is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. augmented betamethasone dipropionate ointment is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m), betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m) - betamethasone acetate 3 mg in 1 ml - when oral therapy is not feasible, the intramuscular use of betamethasone sodium phosphate and betamethasone acetate injectable suspension is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency.  synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular

European Union - English - EMA (European Medicines Agency)

bayer ag  - interferon beta-1b - multiple sclerosis - immunostimulants, - betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.

New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - phenmedipham; metamitron; desmedipham; ethofumesate - phenmedipham 60 g/litre; metamitron 200 g/litre; desmedipham 60 g/litre; ethofumesate 60 g/litre - herbicide - herbicide - group c1+n

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - interferon beta-1b, quantity: 0.25 mg/ml - injection, powder for - excipient ingredients: albumin; mannitol - betaferon is indicated for the treatment of: - ambulatory patients with relapsing-remitting multiple sclerosis (ms) characterised by at least two attacks of neurologic dysfunction over a two year period followed by complete or incomplete recovery. - betaferon is also indicated for the reduction of frequency and severity of clinical relapses, and for the slowing of progression of disease in patients with secondary progressive multiple sclerosis. - the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (mri) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - betamethasone valerate 0.127% equivalent to betamethasone 0.105%. plus 5% overage to ensure potency; betamethasone valerate 0.127%{relative} equivalent to betamethasone 0.105%. plus 5% overage to ensure potency - scalp lotion - 0.1 % - active: betamethasone valerate 0.127% equivalent to betamethasone 0.105%. plus 5% overage to ensure potency excipient: carbomer isopropyl alcohol purified water sodium hydroxide active: betamethasone valerate 0.127%{relative} equivalent to betamethasone 0.105%. plus 5% overage to ensure potency excipient: carbomer isopropyl alcohol purified water sodium hydroxide

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - betamethasone as valerate - cream - betamethasone as valerate 0.1 %w/w - betamethasone - betamethasone - betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.